Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)
Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs) Stratigos, A. J., Sekulic, A., Peris, K., Bechter, O., Dutriaux, C., Kaatz, M., Lewis, K. D., Basset-Seguin, N., Chang, A. S., Dalle, S., Fernandez-Orland, A., Licitra, L., Robert, C., Ulrich, C., Hauschild, A., Migden, M. R., Dummer, R., Li, S., Bowler, T., Fury, M. G. ELSEVIER. 2020: S1175–S1176View details for DOI 10.1016/j.annonc.2020.08.2277
View details for Web of Science ID 000573469102675